全文获取类型
收费全文 | 40244篇 |
免费 | 2769篇 |
国内免费 | 148篇 |
专业分类
耳鼻咽喉 | 264篇 |
儿科学 | 1379篇 |
妇产科学 | 917篇 |
基础医学 | 4647篇 |
口腔科学 | 812篇 |
临床医学 | 4203篇 |
内科学 | 8483篇 |
皮肤病学 | 711篇 |
神经病学 | 3978篇 |
特种医学 | 1304篇 |
外科学 | 6190篇 |
综合类 | 639篇 |
一般理论 | 61篇 |
预防医学 | 3237篇 |
眼科学 | 1007篇 |
药学 | 2825篇 |
中国医学 | 41篇 |
肿瘤学 | 2463篇 |
出版年
2023年 | 126篇 |
2022年 | 215篇 |
2021年 | 603篇 |
2020年 | 382篇 |
2019年 | 638篇 |
2018年 | 768篇 |
2017年 | 616篇 |
2016年 | 621篇 |
2015年 | 801篇 |
2014年 | 1130篇 |
2013年 | 1731篇 |
2012年 | 2639篇 |
2011年 | 2846篇 |
2010年 | 1612篇 |
2009年 | 1471篇 |
2008年 | 2609篇 |
2007年 | 2834篇 |
2006年 | 2781篇 |
2005年 | 2863篇 |
2004年 | 2711篇 |
2003年 | 2502篇 |
2002年 | 2502篇 |
2001年 | 391篇 |
2000年 | 249篇 |
1999年 | 397篇 |
1998年 | 615篇 |
1997年 | 455篇 |
1996年 | 409篇 |
1995年 | 353篇 |
1994年 | 302篇 |
1993年 | 305篇 |
1992年 | 260篇 |
1991年 | 221篇 |
1990年 | 210篇 |
1989年 | 200篇 |
1988年 | 188篇 |
1987年 | 168篇 |
1986年 | 189篇 |
1985年 | 187篇 |
1984年 | 280篇 |
1983年 | 241篇 |
1982年 | 309篇 |
1981年 | 276篇 |
1980年 | 276篇 |
1979年 | 147篇 |
1978年 | 148篇 |
1977年 | 149篇 |
1976年 | 127篇 |
1974年 | 127篇 |
1973年 | 106篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
971.
Matthew S. L. Lee Bharat Ramakrishna Alan C. Moss Howard S. Gold Westyn Branch‐Elliman 《Transplant infectious disease》2020,22(1)
We present a patient with acute myeloid leukemia and prolonged, severe neutropenia who developed fulminant Clostridioides difficile infection refractory to medical therapy and was high‐risk for surgical intervention. He was treated with fecal microbiota transplantation (FMT) for life‐saving cure. The patient had subsequent clinical improvement, however, developed multidrug‐resistant Pseudomonas aeruginosa bacteremia 2 days post‐procedure. We describe subsequent investigation of this event that found this bacteremia was not related to the donor stool administered during FMT. This case adds to the literature that FMT could be considered in heavily immunocompromised patients with fulminant Clostridioides difficile infection where maximal medical therapy has been ineffective and surgery may carry an excessively high mortality risk. 相似文献
972.
973.
974.
975.
A novel biodegradable stent applicable for use in congenital heart disease: Bench testing and feasibility results in a rabbit model
下载免费PDF全文
![点击此处可从《Catheterization and cardiovascular interventions》网站下载免费的PDF全文](/ch/ext_images/free.gif)
976.
Device closure of a pseudoaneurysm of the right ventricular outflow tract in an infant with right ventricle‐to‐pulmonary artery homograft
下载免费PDF全文
![点击此处可从《Catheterization and cardiovascular interventions》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Carrie Herbert MD Catherine Ikemba MD Alan Nugent MBBS 《Catheterization and cardiovascular interventions》2014,83(4):587-590
Pseudoaneurysm of the right ventricular outflow tract (RVOT) is a rare complication following surgical repair of congenital heart disease involving a homograft or conduit. Traditionally, surgical intervention is indicated due to risk for rupture, thrombosis, compression of adjacent structures, and infection. We describe a case of a RVOT pseudoaneurysm in a 5 kg patient that was palliated with interventional catheterization utilizing an Amplatzer Ductal Occluder with four years follow‐up. Interventional catheterization can successfully manage this complication in small patients for the long‐term and thus avoids additional surgery and delays conduit replacement. © 2013 Wiley Periodicals, Inc. 相似文献
977.
When patients with ischaemic heart disease are considered for revascularisation the Heart Team’s aim is to
choose a therapy that will provide complete relief of angina for an acceptable procedural risk. Complete functional revascularisation
of ischaemic myocardium is thus the goal and for this reason the presence of a chronic total occlusion
(CTO) - which remain the most technically challenging lesions to revascularise percutaneously - is the most common reason
for selecting coronary artery bypass surgery [1]. From the behaviour of Heart Teams it is clear that physicians believe
that CTOs are important. Yet when faced with patients with CTOs for whom surgery appears excessive (e.g. nonproximal
LAD) or too high risk, there remains a reluctance to undertake CTO PCI, despite significant recent advances in
procedural success and safety and a considerable body of evidence supporting a survival benefit following successful
CTO PCI. This article reviews the relationship between CTOs, symptoms of angina, ischaemia and left ventricular dysfunction
and further explores the evidence relating their treatment to improved quality of life and prognosis in patients
with these features. 相似文献
978.
979.
Belthrand Habiyakare Hiba Alsaadon Michael L. Mathai Alan Hayes Anthony Zulli 《International journal of experimental pathology》2014,95(4):290-295
Novel treatments are necessary to reduce the burden of cardiovascular disease (CVD). Alamandine binds to MrgD and is reported to induce vasodilation via stimulation of endothelial nitric oxide synthase (eNOS), but its role in atherogenic blood vessels is yet to be determined. To determine the vasoactive role of alamandine and its precursor AngA in diseased aorta, New Zealand White rabbits were fed a diet containing 1% methionine + 0.5% cholesterol + 5% peanut oil for 4 weeks (MC, n = 5) or control (n = 6). In abdominal aorta, alamandine (1 μM) was added 30 min before a dose–response curve to angiotensin II or AngA (1 nM–1 μM), and immunohistochemistry was used to identify MrgD receptors and eNOS. The thoracic aorta, renal, carotid and iliac arteries were mounted in organ baths. Rings were precontracted with phenylephrine, then a bolus dose of alamandine (1 μM) was added 10 min before a dose–response curve to acetylcholine (0.01 μM–10 μM). The MrgD receptor was localized to normal and diseased aorta and colocalized with eNOS. In control but not diseased blood vessels, alamandine enhanced acetylcholine‐mediated vasodilation in the thoracic aorta and the iliac artery (P < 0.05) and reduced it in the renal artery (P < 0.05). In control abdominal aorta, AngA evoked less desensitization than AngII (P < 0.05) and alamandine reduced AngA‐mediated vasoconstriction (P < 0.05). In MC, AngA constriction was markedly reduced vs. control (P < 0.05). The vasoactivity of alamandine and AngA are reduced in atherogenesis. Its role in the prevention of CVD remains to be validated. 相似文献
980.
Eric J. Kezirian George S. Goding Jr Atul Malhotra Fergal J. O'Donoghue Gary Zammit John R. Wheatley Peter G. Catcheside Philip L. Smith Alan R. Schwartz Jennifer H. Walsh Kathleen J. Maddison David M. Claman Tod Huntley Steven Y. Park Matthew C. Campbell Carsten E. Palme Conrad Iber Peter R. Eastwood David R. Hillman Maree Barnes 《Journal of sleep research》2014,23(1):77-83
Reduced upper airway muscle activity during sleep is a key contributor to obstructive sleep apnea pathogenesis. Hypoglossal nerve stimulation activates upper airway dilator muscles, including the genioglossus, and has the potential to reduce obstructive sleep apnea severity. The objective of this study was to examine the safety, feasibility and efficacy of a novel hypoglossal nerve stimulation system (HGNS®; Apnex Medical, St Paul, MN, USA) in treating obstructive sleep apnea at 12 months following implantation. Thirty‐one subjects (35% female, age 52.4 ± 9.4 years) with moderate to severe obstructive sleep apnea and unable to tolerate positive airway pressure underwent surgical implantation and activation of the hypoglossal nerve stimulation system in a prospective single‐arm interventional trial. Primary outcomes were changes in obstructive sleep apnea severity (apnea–hypopnea index, from in‐laboratory polysomnogram) and sleep‐related quality of life [Functional Outcomes of Sleep Questionnaire (FOSQ)]. Hypoglossal nerve stimulation was used on 86 ± 16% of nights for 5.4 ± 1.4 h per night. There was a significant improvement (P < 0.001) from baseline to 12 months in apnea–hypopnea index (45.4 ± 17.5 to 25.3 ± 20.6 events h?1) and Functional Outcomes of Sleep Questionnaire score (14.2 ± 2.0 to 17.0 ± 2.4), as well as other polysomnogram and symptom measures. Outcomes were stable compared with 6 months following implantation. Three serious device‐related adverse events occurred: an infection requiring device removal; and two stimulation lead cuff dislodgements requiring replacement. There were no significant adverse events with onset later than 6 months following implantation. Hypoglossal nerve stimulation demonstrated favourable safety, feasibility and efficacy. 相似文献